MedTrace Logo

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

NCT05749822 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2026-01-08

No results posted yet for this study

Summary

The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC).

Conditions

Interventions

DRUG

UDCA

UDCA 13-15mg/kg/day

DRUG

Fenofibrate 200mg

Fenofibrate 200mg/day

DRUG

Placebo

1 tablet/ day

Sponsors & Collaborators

  • Xijing Hospital of Digestive Diseases

    lead OTHER

Principal Investigators

  • Ying Han · Xijing Hospital, Air Force Military Medical Universit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-17
Primary Completion
2027-12-01
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05749822 on ClinicalTrials.gov